PE20060149A1 - Formulacion farmaceutica para tratar la infeccion por vih - Google Patents

Formulacion farmaceutica para tratar la infeccion por vih

Info

Publication number
PE20060149A1
PE20060149A1 PE2005000341A PE2005000341A PE20060149A1 PE 20060149 A1 PE20060149 A1 PE 20060149A1 PE 2005000341 A PE2005000341 A PE 2005000341A PE 2005000341 A PE2005000341 A PE 2005000341A PE 20060149 A1 PE20060149 A1 PE 20060149A1
Authority
PE
Peru
Prior art keywords
hiv
hiv infection
pharmaceutical formulation
nucleosid
sch
Prior art date
Application number
PE2005000341A
Other languages
English (en)
Inventor
Pin-Fang Lin
Beata Nowicka-Sans
Gregory Yamanaka
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of PE20060149A1 publication Critical patent/PE20060149A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Abstract

SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE: A) 1-BENZOIL-4-[2-[4-FLUORO-7-(1H-1,2,3-TRIAZOL-1-IL)-1H-PIRROLO[2,3-c]PIRIDINA-3-IL]-1,2-DIOXOETIL]-PIPERAZINA O UNA SAL O SOLVATO DEL MSMO; B) UN AGENTE USADO PARA EL TRATAMIENTO DEL SIDA O INFECCION POR VIH SELECCIONADO ENTRE INHIBIDORES DE LA TRANSCRIPTASA INVERSA DEL VIH NUCLEOSIDOS Y NO NUCLEOSIDOS, INHIBIDORES DE LA PROTEASA DEL VIH, INHIBIDORES CCR5, ENTRE OTROS; C) UN PORTADOR FARMACEUTICAMENTE ACEPTABLE. DICHO AGENTE SE SELECCIONA PREFERIBLEMENTE DE ABACABIR, DIDANOSINA, LAMIVUDINA, DELAVIRDINA, EFAVIRENZ, AMPRENAVIR, INDINAVIR, T-1249, SCH-C,SCH-D, ENTRE OTROS. DICHA COMPOSICION TIENE UN EFECTO PROFUNDO EN LA VIREMIA Y EL PROGRESO DE LA ENFERMEDAD EN EL TRATAMIENTO DE INFECCION POR VIRUS DE INMUNODEFICIENCIA HUMANA (VIH)
PE2005000341A 2004-03-24 2005-03-28 Formulacion farmaceutica para tratar la infeccion por vih PE20060149A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US55576804P 2004-03-24 2004-03-24

Publications (1)

Publication Number Publication Date
PE20060149A1 true PE20060149A1 (es) 2006-03-04

Family

ID=34961512

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2005000341A PE20060149A1 (es) 2004-03-24 2005-03-28 Formulacion farmaceutica para tratar la infeccion por vih

Country Status (5)

Country Link
US (1) US20050215544A1 (es)
AR (1) AR048324A1 (es)
PE (1) PE20060149A1 (es)
TW (1) TW200534854A (es)
WO (1) WO2005102328A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060100209A1 (en) * 2004-11-09 2006-05-11 Chong-Hui Gu Formulations of 1-(4-benzoyl-piperazin-1-yl)-2-[4-methoxy-7-(3-methyl-[1,2,4]triazol-1-yl)-1H-pyrrolo[2,3-c]pyridin-3-yl]-ethane-1,2-dione
US20060100432A1 (en) * 2004-11-09 2006-05-11 Matiskella John D Crystalline materials of 1-(4-benzoyl-piperazin-1-yl)-2-[4-methoxy-7-(3-methyl-[1,2,4]triazol-1-yl)-1H-pyrrolo[2,3-c]pyridin-3-yl]-ethane-1,2-dione
PL1942108T3 (pl) 2005-10-28 2014-03-31 Ono Pharmaceutical Co Związek zawierający grupę zasadową i jego zastosowanie
ES2407115T3 (es) 2005-11-18 2013-06-11 Ono Pharmaceutical Co., Ltd. Compuesto que contiene un grupo básico y uso del mismo
US7851476B2 (en) * 2005-12-14 2010-12-14 Bristol-Myers Squibb Company Crystalline forms of 1-benzoyl-4-[2-[4-methoxy-7-(3-methyl-1H-1,2,4-triazol-1-YL)-1-[(phosphonooxy)methyl]-1H-pyrrolo[2,3-C]pyridin-3-YL]-1,2-dioxoethyl]-piperazine
US7501419B2 (en) * 2006-04-25 2009-03-10 Bristol-Myers Squibb Company 4-Squarylpiperazine derivatives as antiviral agents
US7807671B2 (en) * 2006-04-25 2010-10-05 Bristol-Myers Squibb Company Diketo-piperazine and piperidine derivatives as antiviral agents
US7572810B2 (en) * 2006-06-08 2009-08-11 Bristol-Myers Squibb Company Alkene piperidine derivatives as antiviral agents
US7504399B2 (en) * 2006-06-08 2009-03-17 Bristol-Meyers Squibb Company Piperazine enamines as antiviral agents
WO2009158396A1 (en) * 2008-06-25 2009-12-30 Bristol-Myers Squibb Company Diketopiperidine derivatives as hiv attachment inhibitors
ES2462403T3 (es) 2008-06-25 2014-05-22 Bristol-Myers Squibb Company Diceto azolopiperidinas y azolopiperazinas como agentes anti-VIH
WO2012019003A1 (en) 2010-08-06 2012-02-09 Bristol-Myers Squibb Company Substituted indole and azaindole oxoacetyl piperazinamide derivatives
EP2646439B1 (en) 2010-12-02 2016-05-25 Bristol-Myers Squibb Company Alkyl amides as hiv attachment inhibitors
US8685982B2 (en) 2011-04-12 2014-04-01 Bristol-Myers Squibb Company Thioamide, amidoxime and amidrazone derivatives as HIV attachment inhibitors
ES2609579T3 (es) 2011-08-29 2017-04-21 VIIV Healthcare UK (No.5) Limited Derivados espiro de diamina bicíclica como inhibidores de la unión del VIH
EP2751119B1 (en) 2011-08-29 2016-11-23 VIIV Healthcare UK (No.5) Limited Fused bicyclic diamine derivatives as hiv attachment inhibitors
WO2013138436A1 (en) 2012-03-14 2013-09-19 Bristol-Myers Squibb Company Cyclolic hydrazine derivatives as hiv attachment inhibitors
WO2014025854A1 (en) 2012-08-09 2014-02-13 Bristol-Myers Squibb Company Piperidine amide derivatives as hiv attachment inhibitors
ES2616432T3 (es) 2012-08-09 2017-06-13 VIIV Healthcare UK (No.5) Limited Derivados de alquenos tricíclicos como inhibidores de la unión del VIH

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1068219T3 (da) * 1998-03-02 2007-04-30 Univ North Carolina Acylerede betulin- og dihydrobetulinderivater samt fremstilling og anvendelse deraf
US6476034B2 (en) * 2000-02-22 2002-11-05 Bristol-Myers Squibb Company Antiviral azaindole derivatives
US20040110785A1 (en) * 2001-02-02 2004-06-10 Tao Wang Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
US20030207910A1 (en) * 2001-02-02 2003-11-06 Tao Wang Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
NZ533413A (en) * 2001-12-12 2006-09-29 Bristol Myers Squibb Co HIV integrase inhibitors
JP4556020B2 (ja) * 2001-12-21 2010-10-06 ジェンザイム・コーポレーション 高い有効性を有するケモカインレセプタ結合複素環式化合物

Also Published As

Publication number Publication date
US20050215544A1 (en) 2005-09-29
TW200534854A (en) 2005-11-01
WO2005102328A1 (en) 2005-11-03
AR048324A1 (es) 2006-04-19

Similar Documents

Publication Publication Date Title
PE20060149A1 (es) Formulacion farmaceutica para tratar la infeccion por vih
PE20060148A1 (es) Composicion farmaceutica para tratar la infeccion por vih
AR048439A1 (es) Composiciones farmaceuticas y metodos para tratar la infeccion por vih
CO5640076A2 (es) Composicion farmaceutica que comprende un inhibidor de ibat para el tratamiento o profilaxis del estreñimiento
ES2572454T3 (es) Tratamiento de enfermedades mediadas por los linfocitos T
UY26724A1 (es) Métodos y composiciones para tratar el virus de la hepatitis c
MA32018B1 (fr) Vaccin
NO20055585L (no) Templatfikserte beta-harnal peptidhermere med CXCR4 antagonistisk aktivitet
PE20061372A1 (es) Composicion farmaceutica que contiene un vector adenovirus
ECSP055854A (es) Uso de una asociación que contiene un inhibidor no nucleósido de la transcriptasa inversa (nnrti) con un inhibidor de citocromo p450, tales como los inhibidores de la proteasa
PE20080612A1 (es) Metodo de terapia combinada para el tratamiento de la infeccion por el virus de la hepatitis c y composiciones farmaceuticas para usar en dicha terapia
CO6531485A2 (es) Composiciones farmacéuticas sólidas que contienen un inhibidor de la integrasa
BRPI0514724A (pt) inibidores da enzima hiv integrase
ES2151600T3 (es) Derivados de n-(3-amino-2-hidroxibutil)sulfonamida utilizados como inhibidores de proteasa de vih.
Mathes et al. Pre-and postexposure chemoprophylaxis: evidence that 3'-azido-3'-dideoxythymidine inhibits feline leukemia virus disease by a drug-induced vaccine response
CL2022000040A1 (es) Composición farmacéutica que comprende un compuesto de tetrahidropirazolopirimidinona
ECSP22081150A (es) Composición farmacéutica para la prevención o tratamiento de enfermedad infecciosa viral de arn epidémica
CL2007000380A1 (es) Compuestos derivados de pirrolo[3,4-c]pirrol sustituidos; antagonista de los receptores ccr5 de quimioquinas ccr5,composicion farmaceutica;y su uso en el tratamiento o prevencion de infecciones por virus de la inmunodeficiencia humana (vih-1)o pra tratar el sida o el arc.
AR022250A1 (es) Envase farmaceutico de uso para el tratamiento y prevencion de infecciones por el virus de la hepatitis b, procedimiento para el tratamiento de pacientes o pacientes susceptibles en padecer infecciones por el virus de la hepatitis b.
Roberts et al. New opportunities for control of dengue virus
US20210161933A1 (en) Kits for preventing and treating ebola
US20200268856A1 (en) Methods of reactivating latent human immunodeficiency virus and related compositions
US20110206638A1 (en) Compositions and methods for reducing the mutation rate of viruses
Voraphani et al. Matrix metalloproteinase-9 (mmp-9) in children with dengue virus infection
WO2016134202A1 (en) Drug combinations for the treatment of hiv

Legal Events

Date Code Title Description
FC Refusal